REG - CRISM Therapeutics - Result of Retail Offer

CRISM TherapeuticsAnnouncement

Mon 14:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251215:nRSO6299La&default-theme=true

RNS Number : 6299L  CRISM Therapeutics Corporation  15 December 2025

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE
OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, THE
REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD
CONSTITUTE A BREACH OF THE RELEVANT SECURITIES LAWS OF SUCH JURISDICTION.

 

THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND DOES NOT ITSELF
CONSTITUTE A PROSPECTUS OR OFFERING MEMORANDUM OR AN OFFER FOR SALE OR
SUBSCRIPTION IN RESPECT OF ANY SECURITIES IN THE COMPANY. THIS ANNOUNCEMENT
DOES NOT CONSTITUTE OR CONTAIN ANY INVITATION, SOLICITATION, RECOMMENDATION,
OFFER OR ADVICE TO ANY PERSON TO SUBSCRIBE FOR, OTHERWISE ACQUIRE OR DISPOSE
OF ANY SECURITIES OF CRISM THERAPEUTICS CORPORATION IN ANY JURISDICTION IN
WHICH ANY SUCH OFFER OR SOLICITATION WOULD BE UNLAWFUL.

 

THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED TO CONSTITUTE
INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO.
596/2014, AS INCORPORATED INTO UK LAW BY THE EUROPEAN UNION (WITHDRAWAL) ACT
2018 ("UK MAR"). UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE
INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN. IN ADDITION, MARKET
SOUNDINGS (AS DEFINED IN UK MAR) WERE TAKEN IN RESPECT OF CERTAIN OF THE
MATTERS CONTAINED WITHIN THIS ANNOUNCEMENT, WITH THE RESULT THAT CERTAIN
PERSONS BECAME AWARE OF INSIDE INFORMATION (AS DEFINED UNDER UK MAR). UPON THE
PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THOSE
PERSONS THAT RECEIVED INSIDE INFORMATION IN A MARKET SOUNDING ARE NO LONGER IN
POSSESSION OF SUCH INSIDE INFORMATION, WHICH IS NOW CONSIDERED TO BE IN THE
PUBLIC DOMAIN.

 

 

15 December 2025

 

 

CRISM Therapeutics Corporation

("CRISM", "CRISM Therapeutics" or the "Company")

 

Result of Retail Offer

 

Further to the announcement by the Company in respect of the Retail Offer
dated 10 December 2025, CRISM Therapeutics Corporation announces that,
following the closing of the Retail Offer on the BookBuild platform today at
12.00 p.m., the Company has raised gross proceeds of £59,610 (the "Retail
Offer") by way of a subscription of 662,332 Retail Offer Shares at the Issue
Price of 9 pence per share.

 

The proceeds of the Retail Offer together with the Placing announced on 10
December 2025 (together the "Proceeds"), will enable the Company to progress
its MHRA approved, Phase 2 open-label clinical trial of irinotecan-ChemoSeed
in patients with surgically resectable glioblastoma, with first patients
expected to be dosed in Q1 2026.

 

 

Admission and Total Voting Rights

 

Application has been made to the London Stock Exchange for admission of the
Retail Offer Shares ("Admission"). It is expected that Admission will become
effective and that trading will commence in the Placing Shares at 8.00 a.m. on
or around 16 December 2025, or such later date as may be agreed between the
Company and SP Angel. The Retail Offer Shares will rank pari passu with the
Company's existing ordinary shares.

 

Following the issue of the Retail Offer Shares, the total issued share capital
of the Company will consist of 51,735,266 ordinary shares. The Company does
not hold any ordinary shares in treasury. Therefore, the total number of
voting rights in the Company is 51,735,266 and this figure may be used by
shareholders in the Company as the denominator for the calculations by which
they will determine if they are required to notify their interest in, or a
change in their interest in, the share capital of the Company under the FCA's
Disclosure and Transparency Rules.

 

Other than where defined, capitalised terms used in this Announcement have the
meanings given to them in the announcements of 10 December 2025.

 

 

-Ends-

Enquiries:

 Company                         Nomad and Broker                  Financial PR
 CRISM Therapeutics Corporation  S.P. Angel Corporate Finance LLP  Burson Buchanan
 Andrew Webb, Exec. Chair        Richard Morrison (Corp Fin)       Mark Court / Jamie Hooper

 Chris McConville, CSO           Adam Cowl (Corp Fin)              CRISM@buchanancomms.co.uk

                                 Vadim Alexandre (Sales)

                                 Rob Rees (Sales)
 via Burson Buchanan             +44 (0) 20 3470 0470              +44 (0) 20 7466 5000

 

 

About CRISM Therapeutics Corporation

 

CRISM Therapeutics Corporation has developed an innovative drug delivery
technology to improve the clinical performance of cancer treatments for solid
tumours through the local delivery of chemotherapy drugs.

 

ChemoSeed, CRISM's lead product, can be implanted directly into the tumour or
the resection margin following the removal of a tumour. This directs that
therapeutic concentrations of chemotherapy drugs reach the deep-seated tumour
tissue or cover the entire resection margin. In the case of treating
glioblastoma, ChemoSeeds can be implanted during surgery thereby bypassing the
blood brain barrier, which prevents other treatments from being able to reach
the tumour and be effective.

 

CRISM will initiate its registration-grade Phase 2 clinical
trial of irinotecan-ChemoSeed™ in patients with surgically resectable
glioblastoma in Q1 2026.

 

For more information please visit: https://www.crismtherapeutics.com/
(https://www.crismtherapeutics.com/)

 

The Company's LEI is 213800XFW6MKVCHHPW88.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ROITABITMTTBBIA



            Copyright 2019 Regulatory News Service, all rights reserved